Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery

American Journal of Neuroradiology

Volumn 26, Issue 2, 2005, Pages 258-265

  Neuwelt, Edward A ^a,b   Guastadisegni, Paul E ^a   Várallyay, Péter ^a   Doolittle, Nancy D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CHILD; COGNITION; FEMALE; HUMANS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; METHOTREXATE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 27944487750     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Asato R, Akiyama Y, Ito M, et al. Nuclear magnetic resonance abnormalities of the cerebral white matter in children with acute lymphoblastic leukemia and malignant lymphoma during and after central nervous system prophylactic treatment with intrathecal methotrexate. Cancer 1992;70:1997-2004
2. Ebner F, Ranner G, Slave I, et al. MR findings in methotrexate-induced CNS abnormalities. AJNR Am J Neuroradiol 1989;10:959-964
3. Matsumoto K, Takahashi S, Sato A, et al. Leukoencephalopathy in childhood hematopoietic neoplasm caused by moderate-dose methotrexate and prophylactic cranial radiotherapy: an MR analysis. Int J Radiat Oncol Biol Phys 1995;32:913-918
4. Packer RJ, Zimmerman RA, Bilaniuk LT. Magnetic resonance imaging in the evaluation of treatment-related central nervous system damage. Cancer 1986;58:635-640
5. Choucair AK, Scott C, Urtasun R, et al. Quality of life and neuropsychological evaluation for patients with malignant astrocytomas: RTOG 91-14. Int J Radiat Oncol Biol Phys 1997;38:9-20
6. Ahles TA, Silberfarb PM, Herndon JN, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the cancer and leukemia group b. J Clin Oncol 1998;16:1954-1960
7. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627-642
8. O'Neill BP, Wang CH, O'Fallon JR, et al. The consequences of treatment and disease in patients with primary CNS non-hodgkin's lymphoma: cognitive function and performance status. Neuro-Oncology 1999;1:196-203
9. McAllister LD, Doolittle ND, Guastadisegni PE, et al. Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurgery 2000;46:51-61
10. Spiegler BJ, Buoffet E, Mark L., et al. Change in neurocognitive functioning after treatment with cranial radiation in childhood. J Clin Oncol 2004;22:706-713
11. Harder H, Holtel H, Bromberg JEC, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 2004;62:544-547
12. Correa DD, DeAngelis LM, Shi MS, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 2004;62:548-555
13. Meyers CA, Weitzner MA, Valentine AD, Levin VA. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998;16:2522-2527
14. Roman-Goldstein S, Mitchell P, Crossen JR, et al. MR and cognitive testing of patients undergoing osmotic blood-brain barrier disruption with intraarterial chemotherapy. AJNR Am J Neuroradiol 1995;16:543-553
15. DeAngelis LM. Brain tumors. N Engl J Med 2001;344:114-123
16. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-871
17. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-863
18. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-1590
19. Ferreri AJM, Abrey LE, Blay JY, et al. Management of primary central nervous system lymphoma: an international consensus from the 8th International Conference on Malignant Lymphoma (Lugano, June 11, 2002). J Clin Oncol 2003;21:2407-2414
20. Crossen JR, Goldman MD, Dahlborg SA, Neuwelt EA. Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 1991;30:23-29
21. Bleyer WA. Leukoencephalopathy detectable by magnetic resonance imaging: much ado about nothing? Regarding Matsumoto, et al. IJROBP 32:913-918; 1995. [Comment. Editorial] Int J Rad Oncol Biol Phys 1995;32:1251-1252; discussion 1263
22. Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA. Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrom) and survivial. Neurosurgery 2001;48:1033-1041
23. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-647
24. Wechsler D. Wechsler adult intelligence scale. III. San Antonio: Psychological Corporation; 1997
25. Wechsler D. Wechsler memory scale. III. San Antonio: Psychological Corporation; 1997
26. Meyers J, Meyers K. Rey complex figure test under four different administration procedures. Clin Neuropsychol 1995;9:63-67
27. Army individual test battery: manual of directions and scoring. Washington, DC: Adjuvant General's Office; 1944
28. Delis DC, Kramer JH, Kaplan E, Ober BA. California verbal learning test. Research edition. San Antonio: Psychological Corporation; 1987
29. Bornstein RA. Normative data on selected neuropsychological measures from a nonclinical sample. J Clin Psychol 1985;41:651-659
30. Wechsler D. Wechsler intelligence scale for children. III. San Antonio: Psychological Corporation; 1990
31. Wide range assessment of memory and learning. Wilmington, DE: Wide Range;1990
32. Roman-Goldstein S, Goldman D, Howieson J, et al. MR of primary CNS lymphoma in immunologically normal patients. AJNR Am J Neuroradiol 1992;13:1207-1213
33. Ris MD, Packer RJ, Goldwein J, et al. Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a children's cancer group study. J Clin Oncol 2001;19:3470-3476
34. Mulhern RK, Kepner JL, Thomas PR, et al. Neuropsychologic functioning of survivors of childhood mudulloblastoma randomized to receive conventional or reduced dose craniospinal irradiation: a pediatric oncology group study. J Clin Oncol 1998;16:1723-1728
35. Corn BW, Yousem DM, Scott CB, et al. White matter changes are correlated significantly with radiation dose: observations from a randomized dose-escalation trial for malignant glioma. Cancer 1994;74:2828-2835
36. Ball WS, Prenger EC, Ballard ET. Neurotoxicity of radio/chemotherapy in children: pathologic and MR correlation. AJNR Am J Neuroradiol 1992;13:761-776
37. Edwards-Brown MK, Jakacki RI. Imaging the central nervous system effects of radiation and chemotherapy of pediatric tumors. Neuroimaging Clin North Am 1999;9:177-193
38. Butler RW, Hill JM, Steinherz PG, et al. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 1994;12:2621-2629
39. Sands SA, Van Gorp WG, Finlay JL. Pilot neuropsychological findings from a treatment regimen consisting of intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. Childs Nerv Syst 1998;14:587-589
40. Dahlborg SA, Petrillo A, Crossen JR, et al. The potential for complete and durable response in non-glial primary brain tumors in pediatric patients with enhanced chemotherapy delivery. Cancer J Sci Am 1998;4:110-124
41. Brookshire B, Copeland DR, Moore BD, Ater J. Pretreatment neuropsychological status and associated factors in children with primary brain tumors. Neurosurgery 1990;27:887-891
42. Glosser G, McManus P, Munzenrider J, et al. Neuropsychological function in adults after high dose fractionated radiation therapy of skull base tumors. Int J Radiat Oncol Biol Phys 1997;38:231-239
43. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes; osmotic opening and other means. Neurosurgery 1998;42:1083-1100
44. Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology 2002;59:1557-1562